These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37418330)

  • 1. Table: safety of drugs for IBD in pregnancy.
    Med Lett Drugs Ther; 2023 Jul; 65(1680):e113. PubMed ID: 37418330
    [No Abstract]   [Full Text] [Related]  

  • 2. Table: safety of drugs for IBD in pregnancy.
    Med Lett Drugs Ther; 2018 Jul; 60(1550):e116. PubMed ID: 30036355
    [No Abstract]   [Full Text] [Related]  

  • 3. Table: Some drug interactions with drugs for IBD.
    Med Lett Drugs Ther; 2023 Jul; 65(1680):e114. PubMed ID: 37418331
    [No Abstract]   [Full Text] [Related]  

  • 4. Expanded table: Some drugs for inflammatory bowel disease.
    Med Lett Drugs Ther; 2023 Jul; 65(1680):e115-e119. PubMed ID: 37418332
    [No Abstract]   [Full Text] [Related]  

  • 5. Drugs for inflammatory bowel disease.
    Med Lett Drugs Ther; 2023 Jul; 65(1680):105-112. PubMed ID: 37418329
    [No Abstract]   [Full Text] [Related]  

  • 6. Drugs for inflammatory bowel disease.
    Med Lett Drugs Ther; 2018 Jul; 60(1550):107-114. PubMed ID: 30036352
    [No Abstract]   [Full Text] [Related]  

  • 7. Ozanimod (Zeposia) for ulcerative colitis.
    Med Lett Drugs Ther; 2021 Sep; 63(1633):147-151. PubMed ID: 34550962
    [No Abstract]   [Full Text] [Related]  

  • 8. Difficult-to-treat inflammatory bowel disease: Effectiveness and safety of 4th and 5th lines of treatment.
    Caron B; Habert A; Bonsack O; Camara H; Jeanbert E; Parigi TL; Netter P; Danese S; Peyrin-Biroulet L
    United European Gastroenterol J; 2024 Jun; 12(5):605-613. PubMed ID: 38594841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison table: some drugs for inflammatory bowel disease.
    Med Lett Drugs Ther; 2018 Jul; 60(1550):e117-e122. PubMed ID: 30036356
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
    BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis.
    Laube R; Paramsothy S; Leong RW
    Expert Opin Drug Saf; 2021 Mar; 20(3):275-292. PubMed ID: 33412078
    [No Abstract]   [Full Text] [Related]  

  • 12. Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease.
    Innocenti T; Roselli J; Lynch EN; Apolito P; Parisio L; Bagnoli S; Macrì G; Rogai F; Tarocchi M; Milani S; Galli A; Milla M; Dragoni G
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e574-e579. PubMed ID: 35048649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Table: drugs for ulcerative colitis.
    Med Lett Drugs Ther; 2018 Jul; 60(1550):e114. PubMed ID: 30036353
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.
    Rundquist S; Sachs MC; Eriksson C; Olén O; Montgomery S; Halfvarson J;
    Aliment Pharmacol Ther; 2021 Feb; 53(4):471-483. PubMed ID: 33340426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study.
    Atia O; Shavit-Brunschwig Z; Mould DR; Stein R; Matar M; Aloi M; Ledder O; Focht G; Urlep D; Hyams J; Broide E; Weiss B; Levine J; Russell RK; Turner D
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):31-42. PubMed ID: 36306803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
    Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
    Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
    Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
    Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
    Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
    J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab.
    Dupré A; Collins M; Nocturne G; Carbonnel F; Mariette X; Seror R
    Rheumatology (Oxford); 2020 Nov; 59(11):3275-3283. PubMed ID: 32259251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.